会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Pharmaceutical compositions and methods of using secreted frizzled related protein
    • 使用分泌性卷曲相关蛋白的药物组合物和方法
    • US20080166356A9
    • 2008-07-10
    • US10666851
    • 2003-09-19
    • Peter Bodine
    • Peter Bodine
    • A61K39/395A61K38/17A61K48/00
    • A61K38/1709A61K48/00C07K16/18
    • Pharmaceutical compositions and methods of use in regulation of mammalian bone forming activities of sFRPs (secreted frizzled-related proteins) are disclosed. sFRPs are secreted receptors for Wnts, which are important polypeptide growth factors that are known to regulate fundamental biological processes like tissue polarity, embryonic development, and tumorigenesis. A sFRP was isolated from human osteoblast cells and identified as sFRP-1 (also known as SARP-2) and shown to be regulated by osteogenic agents in hOB cells in a differentiation selective manner, modulating the life of osteoblasts/preosteocytes. An sFRP-1 knock-out mouse was generated and deletion of sFRP-1 was found to not affect nonskeletal tissues, skeletal morphology or cortical bone development, while resulting in increased trabecular bone formation, decreased osteoblast and osteocyte apoptosis and increased osteoprogenitor differentiation.
    • 公开了用于调节sFRP(分泌的卷曲相关蛋白)的哺乳动物骨形成活性的药物组合物和方法。 sFRPs是Wnts的分泌受体,其是已知调节基本生物学过程如组织极性,胚胎发育和肿瘤发生的重要多肽生长因子。 从人成骨细胞中分离sFRP,并鉴定为sFRP-1(也称为SARP-2),并以分化选择性方式显示在成骨细胞中由成骨细胞调节,调节成骨细胞/前胚细胞的寿命。 产生sFRP-1敲除小鼠,发现sFRP-1的缺失不影响非骨骼组织,骨骼形态或皮质骨发育,同时导致小梁骨形成增加,成骨细胞和骨细胞凋亡降低,骨祖细胞分化增加。